You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab
Kodiak Sciences Inc. (KOD - Free Report) is making good progress with the development of its lead pipeline candidate, tarcocimab tedromer (formerly KSI-301, also known as tarcocimab), for treating various retinal vascular diseases.
The company is currently evaluating tarcocimab in the phase III study — DAYLIGHT — for treating patients with treatment-naïve wet age-related macular degeneration (wet AMD). Top-line data from the study is expected in mid-2023.
Apart from this, the phase III BEACON study is evaluating tarcocimab in patients with treatment-naïve retinal vein occlusion (RVO).
In August 2022, the BEACON study met the primary endpoint of non-inferior change from baseline in visual acuity at week 24 for subjects dosed with tarcocimab versus Eylea (aflibercept) in patients with macular edema due to RVO. Tarcocimab was generally safe and well tolerated in the study.
Eylea is an anti-VEGF treatment developed by Regeneron (REGN - Free Report) in collaboration with Bayer’s (BAYRY - Free Report) HealthCare unit.
Regeneron/Bayer’s Eylea has been approved by the FDA for multiple retinal indications, including DME, wet AMD and RVO.
While REGN records net product sales of Eylea in the United States, BAYRY records net product sales of Eylea outside the country.
Shares of Kodiak Sciences have plunged 86.6% this year compared with the industry’s decline of 19.2%.
Image Source: Zacks Investment Research
Two phase III studies — GLEAM and GLIMMER —are evaluating tarcocimab for treating patients with diabetic macular edema ("DME").
The GLEAM and GLIMMER studies are designed to evaluate the durability, efficacy and safety of tarcocimab in treatment-naïve patients with DME. Top-line data from the same is expected in mid-2023.
The company is also evaluating tarcocimab in the pivotal phase III GLOW study for treating patients with non-proliferative diabetic retinopathy without DME. Top-line data from the same is expected in the second half of 2023.
KOD remains on course to file a single biologics license application for tarcocimab for treating wet AMD, DME, DR and RVO.
Kodiak Sciences currently has no approved product in its commercial portfolio, hence the company lacks a source for generating regular income. Failure in ongoing studies will hurt the stock. Also, stiff competition from several big companies in the target market remains a headwind.
Kodiak Sciences Inc. Price and Consensus
Kodiak Sciences Inc. price-consensus-chart | Kodiak Sciences Inc. Quote
Zacks Rank & Stock to Consider
Kodiak Sciences currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Achilles Therapeutics plc (ACHL - Free Report) , which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Achilles Therapeutics’ loss per share estimates narrowed 6.4% for 2022 and 9.5% for 2023 in the past 60 days.
Earnings of Achilles Therapeutics surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. ACHL delivered an earnings surprise of 12.45%, on average.